

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on Monday 17th June 2024. I am pleased to confirm the following.

1. For the 4 months from January to April 2024, how many patients received the following intra-vitreous treatments for any eye condition:

Aflibercept	550 patients
Bevacizumab	99 patients
Brolucizumab	36 patients
Dexamethasone	1 patient
Faricimab	0 patients
Ranibizumab – Lucentis	22 patients
Ranibizumab – Ongavia	0 patients

2. For the patients above, how many were new to intra-vitreous treatment? Please provide the patient numbers by the treatments listed below, excluding patients who previously had received any of these treatments.

Aflibercept	12 patients
Bevacizumab	7 patients
Brolucizumab	0 patients
Dexamethasone	0 patients
Faricimab	0 patients
Ranibizumab – Lucentis	1 patient
Ranibizumab – Ongavia	0 patients

Please be advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely

Freedom of Information Co-ordinator
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the
'Re-use of Public Sector Information Regulations' and best practice.